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1. Introduction  
Effective diagnostic and therapeutic intervention of genetic diseases have been particularly 
pending on technological development. It was not until the last two decades of the past 
century that molecular biology and recombinant DNA have provided diagnostic and 
therapeutic tools for these diseases. Since then, our understanding of the biological processes 
underscoring genetic conditions and the development of technologies enabling their study and 
treatment have vastly grown, providing scientists and clinicians with means to continue 
advancing in these directions. Recently, another technology has strongly impacted the fields of 
molecular biology, medicine, diagnostic and therapeutic development: nanotechnology. 
More precisely, nanotechnology focuses on the study and manipulation of matter and 
processes at the nanometer (10-9 m) scale, encompassing the atomic, molecular, and 
macromolecular scales. In this chapter, we use the term nanotechnology from a more broad 
perspective, referring to devices fabricated at the sub-micrometer scale, a size compatible 
with that of large biological macromolecular complexes and cellular organelles, which are 
often referred to as nano- as well, due to the nanoscale of their architectural and/or 
functional components. The application of nanotechnology principles and tools to the field 
of medicine, known as nanomedicine, is also a relatively young field that has vastly 
expanded within the last couple of decades to render new diagnostic and treatment 
approaches. However, delivery of active agents assisted by these technologies is still a 
relatively unexplored strategy in the case of genetic diseases. 
This chapter discusses some of the technological advances regarding the application of 
nanomedicine to the treatment of genetic conditions. Some basic foundation on the design 
and features of these technologies are provided, including targeting, transport, and delivery 
capabilities of drug delivery systems. Applications in the context of genetic diseases are also 
discussed, including treatment of phenotypic symptoms and complications associated to 
these conditions, and correction therapies, such as treatment with small molecules, non-viral 
gene therapies, cell therapies, and enzyme replacement therapies.  
2. Types and properties of drug delivery tools used in nanomedicine 
An area of research where nanotechnology and nanomedicine applications have been 
particularly prolific pertains to delivery of diagnostic and therapeutic agents. Drug delivery 
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carriers are macromolecular assemblies that can incorporate imaging and therapeutic 
compounds of distinct nature, such as small chemicals, fluorophores and biosensors, 
peptides and proteins, and oligonucleotides and genes. They can be designed to improve 
the solubility of these cargo molecules and their bioavailability, and also to control their 
circulation, biodistribution in the body, and release rate, altogether enhancing their efficacy 
(Langer, 1998, Duncan, 2003, Panyam & Labhasetwar, 2003, Moghimi, et al., 2005).  
2.1 Nanocarrier design  
A broad spectrum of materials (biological, synthetic and semi-synthetic) assembled in a variety 
of conformational arrays (from linear structures to branched and dendritic counterparts, 
micelles, hollow capsules, porous or solid particles, etc.) have been designed to help in 
diagnostic and therapeutic interventions (Langer, 1998, Discher & Eisenberg, 2002). Examples 
of these include carbon nanostructures, quantum dots, metal particles, liposomes, and 
formulations based on natural and/or synthetic polymers (Figure 1). The composition and 
architecture of these systems play an important role in determining their translational 
capabilities, including their ability to carry cargoes of different chemistries and their loading 
capacity, stability, biodegradability and overall biocompatibility, and various functional 
aspects (Moghimi, et al., 2001, El-Sayed, et al., 2005, Stayton, et al., 2005, Torchilin, 2006).  
 
 
Fig. 1. Composition and architecture of carriers and other assemblies (not drawn to scale) 
utilized in nanomedicine for diagnosis, imaging, and drug delivery. Yellow, purple, and 
blue colors correspond to formulations discussed in sections 2.1.1, 2.1.2, and 2.1.3. 
2.1.1 Lipid vesicles 
Lipid-based micelles (encapsulating vesicles formed by a single phospholipid layer, ranging 
from ~5 to 100 nm in diameter) and mostly liposomes (vesicles delimited by a phospholipid 
bilayer, with sizes from 50 nm to several micrometers) have been extensively studied for 
more than half a century in the context of transport of diagnostic and therapeutic agents 
(Musacchio & Torchilin, 2011). These vesicles can be constructed with natural lipids, mainly 
derivatives of phosphatidyletanolamine, phosphatidylcholine, phosphatidylserine, and 
phosphatidylglycerol, to mimic cellular membranes. Because phospholipids can 
spontaneously form lipid bilayer-contained capsules in aqueous solution, hydrophilic 
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molecules can be loaded within the inner volume of the vesicle or attached on the liposome 
surface, while hydrophobic cargo can be embedded within the bilayer. Targeting moieties 
with affinity to markers in the body, imaging molecules, and/or polymer coats (discussed 
below) can be incorporated on the surface in order to enhance their circulation, provide 
selective targeting, and improve transport (Minko, et al., 2006, Musacchio & Torchilin, 2011).  
Yet, liposomes can only bear a relatively low degree of said modifications, rendering them 
relatively unstable and susceptible for rapid clearance, mainly due to deposition of plasma 
immunoglobulins and proteins on their surface, favoring uptake by macrophages of the 
reticuloendothelial system (Moghimi & Szebeni, 2003). New approaches are combining 
polymers with liposomal formulations to improve these aspects (Musacchio & Torchilin, 2011).  
2.1.2 Polymer nanocarriers 
Polymers are macromolecules that result from covalent linkage of smaller structural units or 
repeats referred to as monomers, and can be designed from fully synthetic to biological 
blocks (Moghimi, et al., 2001). Some examples of synthetic polymers employed in drug 
delivery include chemically inert and non-toxic materials such as poly(methyl 
methacrylate), poly(acrylic acid), polyacrylamide, poly(vinyl alcohol), and poly(ethylene 
glycol), among many others. Biological polymers include (but are not restricted to) natural 
gums, polysaccharide-, and polypeptide-based formulations (e.g., chitosan, sodium alginate, 
gelatin, albumin, etc.). Also commonly used due to their biocompatibility and ability to be 
degraded in the body are polyanhydrides, polyorthoesters, polycaprolactone, polylactides, 
polyglycolides, and poly(lactide-co-glycolides). These carriers encompass linear polymers, 
branched polymers and tree-like hyperbranched dendrimers, self-assembled polymersomes 
(the polymer counterpart of liposomes), and more stable particles, with overall sizes ranging 
from a few nanometers to several micrometers (Torchilin, 2006). They can endure a degree 
of modification higher than that of lipososomes, rendering multifunctional formulations that 
can carry therapeutics, targeting moieties, and imaging agents (Duncan, 2003). 
Among them, the polyether poly(ethylene glycol), a polymer of ethylene oxide also known 
as PEG (Figure 2B in section 2.2.1), is one of the polymers most broadly used in 
nanomedicine due to its high hydrophilicity and, hence, its ability to solubilize hydrophobic 
drugs, minimize interaction with the immune system, and prolong the circulation of 
compounds (Moghimi, et al., 2001, Panyam & Labhasetwar, 2003). PEG can be directly 
linked to the therapeutic cargo of interest (oligonucleotides or DNA, proteins, small 
molecules, etc), or it can be coupled to or grafted onto other carriers (Moghimi, et al., 2003).  
Poly(lactide-co-glycolide), known as PLGA, is an FDA-approved material that is also 
commonly used for drug delivery due to its biocompatibility: PLGA is hydrolyzed into 
lactic and glycolic acids with minimal toxicity (Mundargi, et al., 2008) and the rate of 
degradation can be adjusted by modification of the particle size and the lactide-to-glycolide 
ratio for controlled release of the cargo (Panyam & Labhasetwar, 2003). In addition, endo-
lysosomal escape of PLGA carriers can be regulated to some extent by modifying these 
design parameters (Panyam, et al., 2002), which is useful for gaining access to other cell 
compartments. This is also a property of cationic polymers, such as poly-L-lysine and 
poly(ethylenimine) (PEI), whose amine groups become protonated at endosomal pH, 
resulting in osmotic swelling that bursts the endosome (Sonawane, et al., 2003). Although 
these polymers are useful for transfection in cell cultures, due to toxicity, other experimental 
formulations more amenable for in vivo applications are being explored. This is the case for 
pH-sensitive poly(acrylic acid) derivative carriers that act as proton sponges within 
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lysosomes, and temperature-responsive polyelectrolyte hydrogels whose hydration rate 
varies with temperature, leading to changes in the carrier volume within the endo-
lysosomal compartment (Yessine & Leroux, 2004, El-Sayed, et al., 2005, Choi, et al., 2006).  
Also natural polymers, such as chitosan, are often exploited for their pH sensitivity and 
bioadhesive properties. Chitosan is cationic under neutral or basic conditions, favoring 
adhesion to negatively-charged membranes of cells, and is depolymerized under acidic 
conditions, resulting in pH controlled drug release (Agnihotri, et al., 2004). Since chitosan is 
mucoadhesive and favors permeabilization through the gastrointestinal epithelial layer, this 
polymer is particularly useful to deliver agents by the oral route (Agnihotri, et al., 2004). 
Polymer dendrimers are also suitable for transport across the intestine due to their small 
size and ability to enhance permeability of the epithelial layer (Kitchens, et al., 2005).  
2.1.3 Carbon nanostructures, metal particles and quantum dots 
In addition to liposomes and (synthetic or natural) polymer carriers, carbon nanostructures, 
quantum dots, and metal particles are becoming more commonly used in nanomedicine. 
These materials are often employed in the design of biosensors for diagnostic applications, 
and also some derivatives have been studied in the context of drug delivery.  
Carbon nanostructures (~1-3 nm diameter, (Chen, et al., 2003)), such as single- or multi-
walled carbon nanotubes, carbon nanospheres, extended carbon nanocube networks, etc., 
possess interesting physical properties suitable for applications in nanotechnology, 
electronics, and optics. They are highly stable and versatile in terms of their structural 
conformation, charge, strength, flexibility, etc. (Cheung, et al., 2010). This material can 
also be functionalized with drugs and/or biomolecules for diagnostic and therapeutic 
purposes.  
Quantum dots (QDs) are semiconductors fabricated from a combination of metals and 
non-metals (Choi & Frangioni, 2010). These nanoparticles (~2-10 nm diameter) have 
unique photophysical properties, e.g., upon excitation they emit fluorescence that is 
brighter and more stable than that of traditional fluorophores, and their size can be varied 
to achieve excitation and emission at different wavelengths. They can be detected with 
high sensitivity, which along with their stability, provides an ideal ground for the design 
of ex vivo screening technologies, such as the case of effective diagnosis of genetic diseases 
(Bailey, et al., 2009).  
Metal nanoparticles are also used in biosensors due to their charge, high sensitivity, and 
output stability. Gold is often used for imaging and biosensing due to its biocompatibility 
and unique optical sensitivity (Cai, et al., 2008). Phosphor particles contain rare earth metals 
and have similar characteristics as QDs, being highly photostable and rendering virtually no 
autofluorescence, yet their larger size limits their applications (Corstjens, et al., 2005).  
While the formulations described above are mostly employed for ex vivo diagnostic 
applications due to toxicity, iron oxide nanoparticles, preferentially 10-100 nm in size 
(Shubayev, et al., 2009), which can be additionally coupled to polymers, are being explored 
for imaging and drug delivery. These carriers can be functionalized with various cargoes 
and have been shown to be relatively suitable for transport of therapeutics (Shubayev, et al., 
2009). They present low toxicity, being biocompatible for in vivo applications. Iron oxide 
and, particularly, superparamagnetic iron oxide (SPIO) nanoparticles exhibit magnetic 
properties, which is used for MRI imaging (Kamaly & Miller, 2010) and also provides an 
opportunity to control particle transport by external magnets (Nacev, et al., 2010). 
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2.2 Pharmacokinetics, targeting, and sub-cellular transport of nanocarriers 
Development of effective diagnostic techniques and therapeutic delivery methods carry a 
number of important challenges, many of which may be overcome with the input of 
nanomedicine approaches. The size scale of nanomedicines and the degree of manipulation 
to which they can be subjected, make these endeavors seemingly tangible. Drug delivery 
carriers can be functionalized to improve control of their circulation and biodistribution in 
the body at the tissue, cellular, and sub-cellular level. This can be achieved by incorporating 
immune-evading moieties and/or affinity molecules that favor adhesion to either general or 
specific biological markers, depending on the degree of selectivity required. In addition, 
when carriers are targeted to cellular receptors involved in endocytic transport or coupled to 
cell penetrating peptides, or if they are designed to modify the permeability of cellular 
barriers, they also provide delivery to a variety of intracellular compartments, such as the 
lysosome, cytosol, nuclei, etc., and can furthermore be transported at some extent across 
cellular layers, a requirement for a number of clinical goals (Langer, 1998, Moghimi, et al., 
2001, Panyam & Labhasetwar, 2003, Sahay, et al., 2010, Sawant & Torchilin, 2010). 
2.2.1 Circulation and clearance 
When administered in vivo, therapeutic agents are often recognized as foreign substances 
and, consequently, are rapidly cleared from the body (Moghimi, et al., 2001, Yoo, et al., 
2010). This is a general obstacle of classical means of drug delivery that also applies to 
chemicals used as palliative treatment of symptoms associated to genetic diseases, and 
more specific small molecules used to regulate affected metabolic pathways, inhibitors 
and activators of the affected molecules, chaperones to improve folding and stability, and 
recombinant proteins and enzymes used for replacement therapies. Clearance of foreign 
compounds in the body occurs mainly by the reticuloendothelial system and other 
elements of the immune system, as well as by renal filtration (Moghimi & Szebeni, 2003). 
Resident macrophages in the alveoli remove substances administered into the lungs 
through the respiratory tract, Kupffer’s cells in the liver sinusoids remove materials that 
enter the portal circulation through the gastrointestinal epithelium, materials 
administered in the systemic circulation are cleared mainly by the spleen and liver, and 
the lymph nodes remove substances that arrive to the tissue parenchyma by draining 
them through the lymphatics.  
For most applications, including those designed for treatment of genetic conditions, e.g., 
mostly applicable to small molecule therapies and enzyme replacement therapies, rapid 
clearance is detrimental as it minimizes the chances of the delivered agent to reach its 
targets in the body and accumulate there at amounts amenable to render significant efficacy. 
Avoiding recognition by said clearance systems, e.g., by designing immune evasive 
strategies leading to lengthening of the life-span of the cargo, can improve the efficiency.  
One strategy to control this parameter consists of coupling to poly(ethylene glycol) or PEG, 
known as PEGylation or stealth technology. PEG helps form a hydrophilic brush around 
cargoes and/or their carriers, minimizing interactions with plasma opsonins, the 
complement, professional phagocytes, and lymphocytes which provide specific immunity 
(Moghimi & Szebeni, 2003) (Figure 2A and 2B). As a consequence, certain physiochemical 
properties of the cargo (such as hydrophobicity) are altered, allowing the platform to gain 
solubility and to remain elusive from immune detection. This prolongs the circulation in the 
bloodstream from a few hours to days, which favors lengthened medicinal effects and less 
frequent administrations (Moghimi & Szebeni, 2003, Musacchio & Torchilin, 2011). 
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Fig. 2. Strategies to minimize rapid clearance of nanocarriers. (A) Poly(ethylene glycol) or 
PEG minimizes interaction with plasma proteins and binding to macrophages. (B) CD47 
binding to the surface of immune cells inhibits engulfment and phagocytosis.  
Other strategy to minimize drug removal takes advantage of the natural mechanism by 
which red blood cells in the body avoid clearance by elements of the innate immune system. 
This is the case for CD47 (Figure 2C), a transmembrane protein that acts like a marker of the 
“self” by binding to its cognate receptor expressed on leukocytes, inhibitory receptor signal 
regulatory protein alpha (SIRPα). CD47 binding to SIRP inhibits phagocytosis, in part  via 
regulation of the cytoskeleton and inhibition of engulfing structures. Incorporation of CD47 
on drug carrier surfaces reduces attachment to neutrophils and macrophages, therefore 
prolonging circulation and inhibiting inflammation (Stachelek, et al., 2011). 
In addition to controlling the solubility level, half-life in circulation, and immune system 
recognition, nanocarriers can also improve control of the drug efficacy upon release in the 
case of therapeutic interventions where administration is local. Localized implantation of 
bioactive agents embedded within porous matrices and/or hydrogels capable of responding 
to microenvironment properties can provide controlled release and effects (Tokarev & 
Minko, 2010). Encapsulation within these formulations can also provide sustained release 
over prolonged periods of time, as oppose to bulk delivery of a naked therapeutic (Tokarev 
& Minko, 2010), which can apply to the release of encapsulated drugs and also bioactive 
substances produced by cells encapsulated within these matrices (discussed in section 3.4).  
2.2.2 Targeting  
As described above, nanomedicines can improve the bioavailability and pharmacokinetics 
of diagnostic and therapeutic agents, also protecting them from rapid degradation. In order 
to maximize their efficacy, carriers can also be designed to help maximize bioadhesion to 
areas in the body where their action is required, a strategy known as targeting (Figure 3).  
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Fig. 3. Passive (A) and active (B) targeting of drug carriers helps localize their cargo within 
the body, either via non-specific interactions with the target cells (i) or more specific 
recognition of particular surface markers (ii). 
In some cases, general enhanced delivery throughout the body, rather than specific delivery 
to particular organs, is preferred. This is the case for genetic conditions that affect multi-
organ systems due to ubiquitous distribution of the molecular markers or functions affected, 
such as in many monogenic disorders with both peripheral and central nervous system 
components. Since most therapeutics do not present intrinsic affinity to cells in the body, 
coupling them to carriers with affinity properties provides advantages. Hydrophilic and 
slightly positively-charged polymers provide affinity to the negatively-charged plasma 
membrane of cells (Panyam & Labhasetwar, 2003, El-Sayed, et al., 2005). Also, these systems 
can be coupled to affinity moieties that enhance bioadhesion. This is the case for 
promiscuous affinity peptides such as Tat, antennapedia, and other sequences that gain 
access to the plasma membrane of cells due to their positively-charged nature (Suk, et al., 
2006, Sawant & Torchilin, 2010) (Figure 3Bi), similarly to polymer carriers described above.  
In other cases, more specific localization of drug cargoes and imaging agents is necessary for 
optimal effects, such as the case of diseases with more prominent symptoms in particular 
organs or cell types (Langer, 1998, Torchilin, 2006, Pardridge, 2010). Moreover, such specific 
targeting may also reduce potential side effects of the therapeutic in non-intended targets. 
For instance, carriers injected in the circulation are passively targeted to organs irrigated by 
the vascular bed immediately downstream the area of administration (first pass 
phenomenon), such as the case of pulmonary accumulation of carriers administered 
intravenously. Also, nanocarriers can gain preferential access to organs irrigated by 
discontinuous blood vessels (Figure 3A), which do not pose a barrier from free diffusion of 
substances between the circulation and tissue, such as in the liver, an organ considered a 
main therapeutic target for many monogenic diseases that affect metabolic pathways.  
However, delivery of therapeutics to most other sites in the body requires more complex 
and precise strategies of active targeting. This can be achieved by coupling to affinity 
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moieties that recognize specific markers expressed by the cells which require intervention 
(Figure 3Bii), including natural ligands of such markers, proteins and peptides, antibodies 
and their fragments, sugars, and aptamers. Also, targeting to markers that are expressed 
under certain pathological processes (as opposed to control physiological conditions) helps 
favoring delivery to disease sites (Muro & Muzykantov, 2005, Bareford & Swaan, 2007). 
Whether it is due to targeting via positively-charged moieties or by specific affinity means, 
targeted delivery of drug carriers offers advantages over direct targeting of therapeutics. 
Apart from the described advantages posed by increased solubility, circulation time, and 
release control, carriers bearing multiple copies of an affinity moiety display greater affinity 
due to this multivalency, compared to drugs that are directly coupled to one copy of the 
same affinity molecule (Muro, et al., 2006a). As described below, multivalency of targeted 
carriers also provides tight binding to cell surface receptors, which can favor uptake within 
the cell, a necessary requirement for many diagnostic and therapeutic applications.  
2.2.3 Sub-cellular transport 
For most applications the molecular targets for intervention are intracellular (Langer, 1998, 
Torchilin, 2006). Therefore, targeting to selected cells and tissues is not sufficient to attain 
significant effects, the delivered cargoes must also gain access to intracellular compartments 
where their molecular targets are located. Interventions related to RNA interference or 
delivery of antisense oligonucleotides require transport of these cargoes to the cytosol of the 
cell, where the target is accessible. This is also the case for delivery of some chaperones, 
inhibitors or activators, enzymes and other proteins located in the cytosol or sub-cellular 
organelles such as the mitochondria, peroxisomes, etc., which can be re-directed to these 
compartments by signal peptides if delivered previously to the cytosol. Gene therapies also 
require delivery to the cytosol, with subsequent transport to the cell nucleus. In all these 
cases, cytosolic delivery can be granted mainly by two routes: direct transport of the cargoes 
and/or their carriers from the extracellular space to the cytosol of cells, or engulfment by the 
plasma membrane and uptake into vesicular compartments (Muro & Muzykantov, 2005, 
Suk, et al., 2006, Bareford & Swaan, 2007, Sahay, et al., 2010).  
Several strategies have been designed to directly overcome the plasmalemma, gaining 
access to the cytosol. These include physical means such as electroporation and ultrasound, 
where a local electric or ultrasound pulse is exerted in the immediate post-administration 
period, causing transient enhancement of the plasmalemma permeability (Trollet, et al., 
2008), and biolistic particle delivery systems, where penetration into cells is gained by 
means of tungsten or gold particles that are propelled by a “gene gun” across the plasma 
membrane (O'Brien, et al., 2001). Other methods providing a similar outcome relate to 
polycationic lipids used to assist cell transfection, which can bind negatively charged 
proteoglycans at the cell surface and favor cytosolic delivery by porating the plasmalemma 
(Dincer, et al., 2005, Zuhorn, et al., 2005). Positively-charged cell penetrating peptides (such 
as RGD and Tat peptides) also bind to the cell surface due to electrostatic interactions and 
can facilitate cytosolic delivery of cargoes (Magzoub, et al., 2005, Suk, et al., 2006).  
As opposed to gaining access to the cell interior by direct penetration into the cytosol, 
uptake within endocytic vesicles and subsequent selective permeabilization of these 
compartments for cytosolic release is another major area of research regarding the design of 
precise nanomedicines (Figure 4A). For instance, drug carriers can be targeted to cell surface 
receptors involved in endocytosis (Muro & Muzykantov, 2005, Bareford & Swaan, 2007, 
Pardridge, 2010, Sahay, et al., 2010). This term refers to a group of processes by which cells 
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engulf extracellular material with their plasma membrane, followed by pinching off the 
resulting vesicles into the cytosol. Uptake by endocytosis is regulated by numerous 
pathways (clathrin- and caveolar-mediated mechanisms, macropinocytosis, phagocytosis, 
and other non-classical mechanisms), and most commonly results in transport of the 
internalized materials to endosomes and lysosomes (Bareford & Swaan, 2007, Sahay, et al., 
2010). This strategy is ideal in the case of delivery of therapeutic agents whose action is 
required at said sub-cellular compartments, such as in the case of carrier-assisted delivery of 
enzyme replacement for lysosomal storage disorders (Figure 4A right) (Garnacho, et al., 
2008, Muro, et al., 2008, Muro, 2010, Hsu, et al., 2011).  For those cases where delivery to the 
cytosol and access to other sub-cellular compartments is required (Figure 4A left), carriers 
can be coupled to fusogenic peptides derived from bacterial toxins (e.g., hemaglutinnin and 
GALA peptides), which can induce poration of the endosomal membrane in response to 
gradual pH lowering in these compartments (Kakudo, et al., 2004). Carriers themselves can 
also be designed to overcome endosomal membranes, such as in the case of pH-sensitive 
poly(acid) carriers and temperature-responsive poly(electrolyte) hydrogels (Yessine & 
Leroux, 2004, Stayton, et al., 2005, Choi, et al., 2006, Oishi, et al., 2006).  
 
 
Fig. 4. Sub-cellular delivery of nanocarriers. (A) Endocytosis of carriers can lead to transport 
to endosomes and lysosomes, where acidic pH and hydrolases can degrade the carrier 
components and release the therapeutic cargo. Alternatively, pH-sensitive carriers can 
destabilize the endosome, releasing the cargo to the cytosol. (B) Transport across cellular 
layers can take place either via paracellular transport between adjacent cells or via 
transcytosis across the cell body (by vesicular mediated endocytosis and exocytosis). 
Finally, effective accumulation within particular tissues requires penetration across cellular 
barriers. This is most evident in the example of diagnostic and therapeutic agents aimed to 
exert their activities in the central nervous systems (Pardridge, 2010), and those which need 
to be transported across the gastrointestinal epithelial layer upon oral administration 
(Kitchens, et al., 2005, Serra, et al., 2009, Park, et al., 2011). In addition, except for a few cases 
www.intechopen.com
 
Human Genetic Diseases 250 
of vascular beds characterized by discontinuous endothelium where free diffusion is 
granted, transport of substances from the bloodstream into the irrigated tissues is regulated 
by the layer of endothelial cells that separate the microvascular wall from the tissue 
parenchyma and this poses an obstacle to penetration (Pardridge, 2010). Transport of 
hydrophilic and/or relatively large substances (molecular chaperones, proteins and 
enzymes, polysaccharides, and oligo- and poly-nucleotides) across endothelial or epithelial 
barriers is restricted to the transcellular or paracellular routes (Figure 4B). The transcellular 
route involves internalization of materials on the apical membrane via endocytosis, traffic of 
endocytic vesicles across the cell body, and exocytosis at the basolateral membrane 
(transcytosis; Figure 4B left), which occurs mainly via clathrin- and caveolar-mediated 
pathways (Muro, et al., 2004, Bareford & Swaan, 2007). Due to its safety, this route is 
preferred for transport into the central nervous system, which can be achieved to some 
extent by targeting receptors such as the folate, insulin, low density lipoprotein, and 
transferrin receptors (Hilgenbrink & Low, 2005, Pardridge, 2010, Musacchio & Torchilin, 
2011). The paracellular pathway (Figure 4B right) involves transport between adjacent cells 
via regulation of the junctions that interlock them (Dejana, 2004). This may lead to more 
uncontrolled, passive transport compared to the transcellular route, hence it is less desired 
in gaining access into the brain, whereas it seems relatively safe for transport across the 
gastrointestinal epithelium in oral applications (Kitchens, et al., 2005, Park, et al., 2011). 
3. Nanomedicine applications for treatment of genetic diseases  
Several properties of nanomedicine designs, mainly pertaining their biocompatible size and 
high degree of manipulation that allow adaptation to different biomedical applications, have 
caused this field to be considered a new technological revolution. Nanotechnology has opened 
new possibilities for ex vivo detection methods (e.g., applicable to mutation screening) as well 
as biomarkers of disease, with several technologies being also applicable for in vivo imaging 
(Cai, et al., 2003, Corstjens, et al., 2005, Bailey, et al., 2009, Cheung, et al., 2010, Choi & 
Frangioni, 2010). These strategies are considerably more sensitive than traditional methods, 
permitting detection in smaller samples and/or providing more accurate measurements and 
tracings of the parameters of interest. From the therapeutic perspective, nanomedicine 
strategies hold considerable promise to improve control parameters such as the solubility, 
stability, clearance, biodistribution, sub-cellular transport, controlled release of therapeutic 
cargoes of diverse nature, improving their efficacy and minimizing potential side effects 
(Langer, 1998, Moghimi, et al., 2001, Stayton, et al., 2005, Torchilin, 2006).  
For the most part, these technologies are still at the experimental stage, particularly those 
that require in vivo administration as opposed to those designed for ex vivo diagnosis and 
detection. However, research has shown a great potential of these platforms for clinical 
translation in the near future, with some examples being already available in the market, 
mostly in the case of cancer therapeutics. Although relatively unexplored in the case of 
genetic deficiencies, the use of nanomedicine principles and strategies for diagnosis and 
treatment of these conditions is a rapidly growing field with highly promising perspectives. 
3.1 Small molecule therapy 
Small molecule therapy typically encompasses chemicals used either for palliative care of 
symptoms or more specifically designed to cope with a particular landmark that regulates 
disease progression. In many cases, their small size and chemical properties are relatively 
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permissive of diffusion through the body and cells, with relatively good efficacy. However, 
in other cases they suffer from the obstacles discussed in section 2.2 above, including rapid 
clearance, inactivation, and sub-optimal access through biological barriers.  
For instance, when delivered intravenously rapid loss of therapeutic activity may arise from 
the direct interaction with blood components and elements of the reticuloendothelial or 
immune systems. This can be prevented by encapsulating small molecule therapeutics 
within carriers designed to minimize interaction with said clearance or inactivating systems, 
prolong their circulation, enhance their accumulation in certain areas of the body, and 
control their release over long periods of time. Some examples of such applications in the 
realm of intravenous administration of small molecule therapies for genetic conditions have 
been reported, such as the case of treatment of hemophilia with coagulation factors 
encapsulated in biocompatible liposomes, which prolongs the therapeutic window (Yatuv, 
et al., 2010), or enhanced efficacy of liposomal formulations of antibiotics to treat lung 
infections in cystic fibrosis (CF) (Mugabe, et al., 2005, Rukholm, et al., 2006). In other cases, 
interaction with blood components is desired, yet formulation as a nanocarrier still provides 
therapeutic advantages, such as the case of hexadentate-terminated hydroxypyridinone-
based dendrimers, an iron chelating formulation that has been shown to effectively 
sequester excess iron in haemochromatosis and the thalassaemias (Zhou, et al., 2006).  
Regarding penetration in the body, nanomedicine formulations can also help by providing 
means to modulate viscosity of physiological barriers, such as the sputum in the lungs in the 
case of inhaled drugs, or enhance the permeability of cellular barriers, such as that 
encountered by oral drugs in the gastrointestinal epithelium or small molecules that can not 
cross from the bloodstream into the brain. For instance, the thick lung sputum encountered 
in CF patients is a major obstacle for effective penetration of classical inhaled therapeutics, 
hindering access to the underlining epithelial layer. Encapsulation of antibiotics within 
liposomes modified with amiloride hydrochloride has been shown to force water retention 
and reduce viscosity of the sputum, resulting in enhanced release and effects (Chougule, et 
al., 2006). Liposomes modified with the bioadhesive metal, gallium, improved delivery of 
antibiotics in the CF airways, permitting reduction of the administered dose by an order of 
magnitude compared to the naked antibiotic (Halwani, et al., 2008). Biodegradable 
PEGylated PLGA nanoparticles have also been shown to effectively cross the sputum, which 
has been used to enhance delivery of proteosome inhibitors in CF (Vij, et al., 2010).  
With regard to delivery of small molecules by the oral route (preferred to minimize cost and 
improve patient compliance), encapsulation in enteric-coated capsules is typically required. 
Classically, bulk capsules protect therapeutics from exposure to the acidic environment in 
the stomach. Coupling to nanocarriers has shown advantages in this arena, particularly 
regarding intestinal absorption. This has been shown in the case of oral delivery of anti-
diabetic agents by solid lipid particles, which effectively decreased glucose in circulation 
(Nnamani, et al., 2010) or the case of PLGA nanocarriers encapsulating curcumin for CF, 
which surpassed the effects of its non-encapsulated counterpart (Cartiera, et al., 2010). 
Similar results were rendered using chitosan nanocarriers designed for pH-sensitive release 
and enhanced mucoadhesive potential, resulting in improved absorption of anti-diabetic 
drugs (Wong, 2010). A combination of classical oral delivery formulations and 
nanotechnologies, e.g., chitosan nanocarriers encased within enteric-coated capsules for 
insulin delivery, has shown enhanced results, reflecting the potential of nanomedicine to 
impact oral delivery of active therapeutics (Cui, et al., 2009, Sonaje, et al., 2010).  
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Another important cellular barrier encountered by some small molecule therapies is that of 
the blood-brain interface, which forces more invasive means of local delivery, including 
direct injection or implantation of the naked therapeutic agent or different scaffolds 
containing said therapeutic into the brain, e.g., by intracerebral or intraventricular, 
administration (Menei, et al., 2000, Nakaji-Hirabayashi, et al., 2009, Emerich, et al., 2010). In 
this regard, prolonged circulation and stability rendered by nanocarriers can enhance the 
chances of drug diffusion into the brain parenchyma. As discussed in section 2.2.3, carriers 
targeted to particular transporters of the blood-brain barrier can also improve entry into the 
central nervous system. Examples illustrating this are those that capitalize on targeting the 
transferrin receptor, which provides transendothelial transport by a clathirn-mediated 
mechanism. This has been explored for delivery of nerve growth factor for Huntingon’s 
disease (Kordower, et al., 1994). Nanocarriers have also been used as vehicles to assist in 
transporting chelating agents into the brain for iron capture and removal in Alzheimer’s 
disease, also with potential in Huntington’s and Parkinson’s diseases (Liu, et al., 2009).  
Similar nanomedicine strategies can improve delivery of other small molecule therapies for 
genetic diseases, including hormones to control regulatory pathways, antibiotics, growth 
factors, cofactors, inhibitors or activators that act upstream or downstream of affected 
pathways, chaperones that favor proper protein folding, and other chemicals.  
3.2 Enzyme therapy 
The term enzyme therapy describes the administration of exogenous enzymes to replace 
their defective endogenous counterparts (enzyme replacement therapy or ERT) and can also 
be extended beyond the treatment of genetic diseases with impaired enzyme production, for 
instance in cases where administration of additional enzymes that are not encountered 
endogenously in the human body can help alleviate phenotypic symptoms. Classical 
examples of the first approach have been applied to the treatment of lysosomal storage 
disorders (LSDs), mostly caused by genetic defects affecting enzymes involved in lysosomal 
degradation of varied substrates (Burrow, et al., 2007), neuropathic phenylketonuria (PKU) 
as a consequence of a defect in phenylalanine hydroxylase (PAH) (Kim, et al., 2004, Harding 
& Blau, 2010), or prolidase deficiency affecting collagen metabolism (Colonna, et al., 2008b), 
among many others. The second approach is illustrated in examples pertaining, for instance, 
administration of alginate lyase to degrade components of infectious biofilms in CF 
(Lamppa, et al., 2011) or delivery of uricase for gout treatment (Sherman, et al., 2008). 
However, effective delivery of enzymes often suffers from the impediments stated above for 
small molecule therapies, with the added disadvantages that arise from using proteins as 
therapeutic agents: susceptibility to proteases, high potential for immunogenicity, and even 
more reduced penetration within tissues and cells in the body. Hence, these therapeutic 
strategies represent good targets for improvement by nanomedicine approaches. 
For instance, several lysosomal ERTs are clinically available, providing a marked 
phenotypic improvement. However, in many cases, production of antibodies against the 
administered recombinant enzymes hinders the efficacy of this treatment over time, which 
represents a major obstacle for treatment of these chronic conditions (Ponder, 2008, 
Linthorst, et al., 2004). This could be ameliorated by encapsulating or coupling said enzymes 
within immuno-evasive carriers or polymers, such as those described in section 2.2.1. Some 
preliminary attempts in this direction include the case of delivery of PEG-modified 
dextranase, which achieved prolonged activity by bypassing immunorecognition in a mouse 
model of LSD mimicked by lysosomal accumulation of dextran (Mumtaz & Bachhawat, 
1994). Similar strategies of PEGylation have been useful for delivery of uricase for gout 
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treatment in hyperuricemia (Sherman, et al., 2008), non-mammalian phenylalanine 
ammonia lyase for treatment of PKU (Ikeda, et al., 2005), or alginate lyase delivery targeted 
to CF infections (Lamppa, et al., 2011).  
In addition to protecting from inactivation and immunogenic responses, by masking the 
enzymes from the immune and clearance systems, it is expected that these strategies 
involving incorporation of PEG in the formulation will also provide prolonged circulation, 
hence enhancing the chances to reach tissues and cell targets in the body, a capacity 
otherwise considerably restricted for large molecules such as these enzymes. Encapsulation 
within or coupling to liposomes and polymer carriers, as well as the incorporation of active 
targeting moieties, may help these aspects. Some examples of these applications were 
explored in the late 70’s, such as in the case of enhanced delivery of glucocerebrosidase 
deficient in Gaucher disease upon encapsulation within liposomes (Dale, et al., 1979), or 
liposomes coupled to aggregated immunoglobulins or apolipoproteins for enhanced 
enzyme targeting to polymorphonucleocytes for treatment of Batten disease (Weissmann, et 
al., 1975, Steger & Desnick, 1977). Yet, not many subsequent works have risen from these 
seminal studies, adapting the rapid evolving arena of nanomedicine to formulations for 
treatment of genetic conditions, and both fields have developed independently. A recent 
attempt to bridge this gap studied enhancement of delivery of acid sphingomyelinase or -
galactosidase (deficient in types A-B Niemann-Pick disease or Fabry disease, respectively) to 
peripheral organs and the brain, which was achieved by coupling said enzymes to polymer 
nanocarriers targeted to intercellular adhesion molecule-1 (ICAM-1), a molecule present in 
multiple tissues and cell types in the body, whose expression is highly upregulated in many 
pathological conditions (Garnacho, et al., 2008, Muro, 2010, Hsu, et al., 2011).  
This type of strategy can not only assists with targeting of enzymes through the body, but it 
can also provide access to intracellular compartments where their action is required, 
improving efficacy. This can be achieved by either exploiting targeting to receptors involved 
in endocytic transport and/or carriers capable of transporting materials across the plasma 
membrane or the membranous envelop of intracellular compartments (described in section 
2.2.3). This is the case for prolidase delivery by chitosan nanoparticles, which enhance 
absorptive endocytosis of the enzyme into cells, with subsequent pH-triggered release to the 
cytosol (Colonna, et al., 2008a), or enhanced delivery of acid sphingomyelinase or -
galactosidase to lysosomal compartments by ICAM-1-targeted nanocarriers (Muro, et al., 
2006b, Garnacho, et al., 2008, Hsu, et al., 2011). In the latter example, ICAM-1 targeting 
provides a means for switching the entry pathway of lysosomal enzymes within cells from 
clathrin-mediated endocytosis, typically induced by binding of mannose or mannose-6-
phosphate residues present on the naked lysosomal enzymes to the corresponding cell 
receptors, to cell adhesion molecule (CAM)-mediated endocytosis induced by ICAM-1 
targeting. This provides an advantage for those cases when the pathology itself tends to 
alter the expression or function of cell receptors, such as the case of the mannose-6-
phosphate receptor in some LSDs (Dhami & Schuchman, 2004, Cardone, et al., 2008). Finally, 
transport across cellular barriers, greatly impaired for many enzyme therapies, could be 
improved by formulating said enzymes as their nanocarrier counterparts, as those described 
in section 2.2.3, enabling these treatment strategies to reach the central nervous system or to 
be converted into oral delivery modalities. 
3.3 Gene therapy 
In a broad definition, gene therapy encompasses the modulation of the expression of genes 
affected in genetic conditions, which can be achieved at the level of providing codifying 
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gene sequences that can enable the transcription and translation of functional proteins 
otherwise affected by these defects, or other regulatory sequences that can up-regulate or 
down-regulate said expression at any stage during transcription or translation. This is 
inclusive of, but not limited to, delivery of cDNA to replace the codifying sequence of the 
affected gene, or delivery of oligonucleotides for correction of mRNA transcripts by mRNA 
insertion/deletion, small interference RNA (siRNA) for silencing, etc.  
This strategy capitalizes on viral vectors, given that many viruses can actively bind to cell 
surface receptors, enter cells by endocytosis, and gain access to the cytosol and the 
nucleus, in certain cases, by escaping the endo-lysosomal vesicles in which they are 
contained (Campbell & Hope, 2005). These viruses have evolved mechanisms capable of 
“sensing” the lowering pH within endosomes and lysosomes, e.g., by protonation of 
amphiphilic molecules, which can then destabilize and porate the endo-lysosomal 
membrane (Campbell & Hope, 2005). Delivery of said nucleic acid-based therapeutics has 
been shown to be markedly effective when using viral vectors, which is attributable to 
their innate ability to effectively deliver double-stranded or single-stranded DNA or RNA 
molecules within cells.  
Most strategies attempted include somatic gene transfer in animal models using adenovirus, 
adeno-associated virus, herpesvirus and, more recently, retrovirus and lentivirus vectors 
capable of integrating the exogenous gene sequences into the host genome for prolonged 
expression (Wilson, 2004, Sands & Davidson, 2006). Other strategies consist of transforming 
cells ex vivo by viral vectors to express functional proteins, with subsequent local 
implantation of the transformed cells in the body (Ohashi, et al., 2000, Karolewski & Wolfe, 
2006). However, while these strategies are highly promising, their current translational 
application is still limited due to cargo size limitations and mainly safety concerns that 
involve immunogenicity and potential for random insertions in the host genome. 
In this regard, nanomedicine offers an opportunity to develop complementary approaches 
to traditional gene therapy. For instance, PEGylation strategies can improve the masking 
from the immune system, such as the case of PEGylated DNA/nanoparticles shown to 
provide effective intraocular transfection for retinitis pigmentosa while avoiding immune 
recognition (Cai, et al., 2008), or PEGylation of adenoviruses to confer protection against 
neutralizing antibodies (O'Riordan, et al., 1999), which may enable subsequent 
administrations. Similarly, encapsulation of the viral vectors themselves within polymer 
materials can also minimize immunogenicity, illustrated by successful gene transduction 
using adenoviruses encapsulated into PLGA microspheres (Turner, et al., 2007).  
Encapsulation or complexation of nucleic acid material within liposomes or polymer carriers 
(lipoplexes or polyplexes) is also being optimized in order to avoid utilization of protein-
rich viral capsids (arguably highly immunogenic) and viral genetic elements. Properties 
such as immune evasion, improved penetration through viscous fluids, targeting to 
particular cellular markers, and membrane permeabilization (those of the plasmalemma or 
intracellular compartments), discussed in section 2.2, are being built in these systems, to 
enable them to achieve delivery of nucleic acid materials. For instance, addition of albumin 
to polyplexes improves penetration through the sputum and provides transfection in CF (Di 
Gioia, et al., 2008). Bioadhesive and pH-responsive properties of chitosan nanoparticles, 
along with its lack of toxicity, can also benefit delivery of gene therapies (Agnihotri, et al., 
2004), including oral gene delivery applications such that of coagulation factor VIII in a 
hemophilia mouse model (Dhadwar, et al., 2010) or glucagon-liked peptide 1 (GLP-1) to 
reduce blood glucose in diabetes (Jean, et al., 2011).  
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As discussed for other therapeutic applications, these nanomedicine strategies can be 
targeted to particular receptors encountered in cells where transfection is needed. As an 
example, this has been shown in the case of lipoplexes encoding for low-density lipoprotein 
receptor (LDLR) and targeted to the tranferrin receptor to provide expression of LDLR for 
treatment of familial hypercholesterolemia (Shichiri, et al., 2003). The same targeting 
strategy has been used for expression of glial-derived neurotrophic growth factor (GDNF) to 
reduce neurotoxicity in Parkinson’s disease (Zhang, et al., 2006).  
Coupling to cell penetrating peptides and/or carrier scaffolds amenable for escaping from 
endocytic compartments (discussed in section 2.2.3), reminiscent of viral escape from these 
vesicles, improves the efficacy of transfection. Examples illustrating these strategies are 
those of facilitated transfection by PEGylated PEI encasing oligonucleotides for Duschenne 
muscular dystrophy, hemophilia, and CF (Lee, et al., 2004, Carrabino, et al., 2005, Dif, et al., 
2006, Sirsi, et al., 2008), lipoplexes coupled to arginine-glycine-aspartic acid (RGD) peptides 
that can bind to integrins (Scott, et al., 2001), or direct coupling of DNA to cell penetrating 
peptides, such as in the case of gene therapy for Fabry disease (Lavigne, et al., 2008).  
3.4 Cell therapy 
Cell therapy has been largely utilized as a therapeutic generating system, where cells from 
healthy subjects or cells from the patient properly modified are implanted in the body to 
provide sustained production of a molecule of interest that is innately defective in the 
diseased patient. Hence, the cell itself can be considered the vehicle of delivery and 
sustained effects can be achieved. This is beneficial in the case of certain proteins, hormones, 
and small molecules (such as neurotrophic factors) that display short circulatory longevity 
and are easily subjected to proteases, shortening their therapeutic effects.  
By directly producing these molecules at the required site, cell therapy provides a means to 
bypass secondary strategies to stabilize said molecules or the necessity for enabling crossing 
of physiological barriers. This is the case for implantation of alginate microparticles carrying 
recombinant fibroblasts for sustained systemic release of -glucuronidase for 
mucopolysaccharidosis VII (Ross, et al., 2000a). Local implantation of the encapsulated cells 
into the brain lateral ventricles circumvents the blood-brain barrier and results in 
considerable delivery of the secreted enzyme (Ross, et al., 2000b).  Similarly, implantation of 
encapsulated, genetically modified fibroblasts capable of producing ciliary neurotrophic 
factor (CNTF), a neuroprotective agent, in the brain or within vitreous humor of the eye 
have been explored in the context of treatment for Huntington’s disease and retinitis 
pigmentosa (Emerich, et al., 1996, Tao, et al., 2002, Bloch, et al., 2004). 
In most of these applications, encapsulation of cells to be implanted within polymer 
matrices is advantageous, if not required, in order to create a protective physical barrier to 
the immune system while permitting sustained release of the therapeutic by the implanted 
cells. Such scaffolds can avoid unwanted cell escape and neoplastic growth, yet allow 
oxygen and nutrients to access the matrix to maintain cell viability, while permitting 
therapeutics to be secreted to the surrounding environment. In this regard, nanotechnology 
has permitted nano-scale manipulation of these materials to achieve controlled diffusion, 
limiting immune response while supporting sustained release of the therapeutic molecules. 
An example of this strategy capitalizes on the use of alginate poly(L-lysine) hydrogels, an 
immune elusive and non-toxic polymer, (Koch, et al., 2003) with a nanoporous architecture, 
suitable to allow minimal yet sufficient nutrient exchange (Desai, et al., 2004).  
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Reduced access to elements of the immune system may also provide an avenue for use of 
allografts or xenografts, as in the case of long term implantation into rats of bovine islet cells 
encapsulated within alginate poly(L-lysine) microcapsules (Lanza, et al., 1999). Similarly, 
this property can be exploited to achieve more sustained therapeutic effects, such as those 
obtained in the case of genetically modified endothelial cells in treatment of hemophilia A, 
effective for ~150 days (Lin, et al., 2002), modified myoblasts to secrete erythropoietin, hence 
reducing the need of constant blood transfusions and hormone injections for treatment of 
the thalassemias (Dalle, et al., 1999), or encapsulated fibroblasts that release GDNF for 
Parkinson’s disease, which was effective for up to 2 years (Zurn, et al., 2001).  
4. Conclusion 
During the last 2-3 decades, the development of nanotechnologies for medical applications 
has provided important new avenues to improve diagnosis and treatment of human 
maladies. Said nanomedicines display a considerable degree of control of parameters such 
as increased solubility of various cargoes, evasion from the immune system, controlled 
circulation, improved stability, enhanced biodistribution in the body, modulatable transport 
into and/or across cells, and controlled release at the final destination. These approaches 
can be applied to the development of sensors and imaging agents with improved detection 
and diagnostic sensitivity, and also delivery of therapeutic strategies pertaining to small 
molecule, enzyme, gene, and cell therapies. Several nanoconstructs with varied chemical 
nature, architectural design, and functional properties have been successfully translated into 
the clinics, mainly for applications other than treatment of genetic conditions. Although, 
their application in this field has been only modestly explored, these systems rather 
represent general platforms, offering a unique opportunity to develop alternative and 
complementary therapeutic interventions applicable to the treatment of genetic diseases.  
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